With the objective of evaluating the safety and tolerability of intravenous immune globulin (IVIG) as a treatment for neuromyelitis optica (NMO), a team of Spanish investigators administered IVIG (0.7 g/kg body weight for three days) every two months to eight patients meeting Wingerchuk’s revised diagnostic criteria for the disorder.
Initial results from a Phase 1 trial of the world’s first HIV vaccine has shown no adverse effects while significantly boosting immunity.
A new study published in Hepatology finds that the prevalence of chronic hepatitis B virus (HBV) infection in the U.S. may be as high as 2.2 million cases.
Researchers from Braasch Biotech in South Dakota have developed an obesity vaccine that stimulates the immune system to attack a hormone that promotes slow metabolism and weight gain.
A desensitization protocol using intravenous immune globulin (IVIG) and rituximab has been used for a number of years to allow renal transplantation in highly sensitized (HS) patients, defined as having panel reactive antibody (PRA) >80 percent.
Results from a new study in patients with early Alzheimer’s disease showed a short course of intravenous immune globulin slows the disease’s progression.
A Phase II clinical trial that is testing the success of a pancreatic cancer vaccine is giving researchers hope that the treatment might be ready for wide distribution within the next couple of years.
VARIZIG, a hyperimmune globulin indicated for post-exposure prophylaxis of varicella zoster virus (VZV) in high-risk patients, has been approved by the U.S.Food and Drug Administration.
Under the Affordable Care Act (ACA),the health insurance sales tax and age-rating restrictions will increase premiums for many, according to a report by Oliver Wyman, a management consulting firm.
The U.S. Food and Drug Administration has approved a new children’s vaccine that targets two common causes of bacterial meningitis.
Octapharma USA’s Octaplas, a solvent/detergent-treated pooled human plasma, has been approved by the U.S. Food and Drug Administration.
A recent survey conducted by the U.S. Centers for Disease Control and Prevention shows that the number of provider sites participating inimmunization information systems has increased.